RAS Mutations in Thyroid Cancer.

RAS Mutations in Thyroid Cancer. Oncologist. 2013 Jul 19; Authors: Howell GM, Hodak SP, Yip L Abstract In recent years, our understanding of the genetic alterations underlying thyroid oncogenesis has greatly expanded. The use of molecular markers, including RAS, in the management of thyroid carcinoma is also increasing. This review summarizes the current literature surrounding RAS and discusses its potential as a diagnostic and prognostic indicator in the management of thyroid cancer. PMID: 23873720 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research

Related Links:

We report the development of hidradenitis suppurativa (HS) in a patient after initiation of treatment with sorafenib. To our knowledge, sorafenib-induced HS in the axillary and inguinal skin folds has not been previously reported. A 33-year-old male on sorafenib for papillary thyroid cancer presented for evaluation of “boils” that began when he initiated chemotherapy 5 years prior and had continued to progress.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Conditions:   BRAF NP_004324.2:p.V600M;   BRAF V600E Mutation Present;   Metastatic Thyroid Gland Carcinoma;   Refractory Thyroid Gland Carcinoma;   Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8;   Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8;   Stage IVB Differentiated T hyroid Gland Carcinoma AJCC v8 Interventions:   Drug: Binimetinib;   Drug: Encorafenib;   Biological: Nivolumab Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute&nbs...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Source: Cancer Biotherapy and Radiopharmaceuticals - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsPhysicians should be aware of the possibility of the emergence of primary malignancies in patients with a history of papillary thyroid carcinoma, especially lung cancer as it is a common site of papillary thyroid carcinoma metastases. Using appropriate diagnostic evaluations in order to choose the best therapeutic option is of utmost importance.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Oleanolic acid (OA) is a naturally occurring triterpenoid that possesses antitumor activity against several tumor cell lines. However, the potential mechanism underlying OA-induced thyroid carcinoma cell death is poorly understood. We investigated the biological functions of OA by performing migration, invasion, colony formation, and apoptosis assays on SW579 cells. Forkhead box A1 (FOXA1) expression was used to predict poor prognosis in patients with thyroid carcinoma among the TCGA samples from the UALCAN and gene expression profiling interactive analysis databases. Western blot was used to detect protein expression leve...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Papers Source Type: research
Thyroid, Ahead of Print.
Source: Thyroid - Category: Endocrinology Authors: Source Type: research
We describe a case of successful in vitro fertilization pregnancy and delivery after a fertility-sparing laparoscopic operation in a patient with papillary thyroid carcinoma arising from a mature cystic teratoma. PMID: 31401818 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Reproductive Medicine - Category: Reproduction Medicine Tags: Clin Exp Reprod Med Source Type: research
Conclusions: In progressive HCC, several treatment options outside or inside clinical trials are available. WGS of metastatic tumors might direct the timing of therapy. Unlike other cancers, the absence of RAS variants seems to provide insufficient justification of single-agent panitumumab administration in HCC cases harboring a near-homozygous genome.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
This study aims to characterize dysregulated immune-associated and cancer-associated genes in three PTC subtypes to explore how the interplay between cancer and immune processes causes differential prognosis. RNA-sequencing data from The Cancer Genome Atlas (TCGA) were used to identify dysregulated genes in each variant. The dysregulation profiles of the subtypes were compared using functional pathways clustering and correlations to relevant clinical variables, genomic alterations, and microRNA regulation. We discovered that the dysregulation profiles of classical PTC (CPTC) and the tall cell variant (TCPTC) are similar an...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Genetics | Thyroid | Thyroid Cancer